Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antihistamines in rhinoconjunctivitis.

Peter Howarth1

  • 1University of Southampton, Southampton, England.

Clinical Allergy and Immunology
|July 13, 2002
PubMed
Summary
This summary is machine-generated.

H1-antihistamines effectively treat allergic rhinoconjunctivitis symptoms like itch and sneezing. Newer topical and oral options offer improved efficacy and reduced side effects, though histamine isn't the sole cause.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps-Are We Comparing Apples With Oranges?

International forum of allergy & rhinology·2026
Same author

Reply to Siddiqui et al., Godbout et al., and to Chang and Mao.

American journal of respiratory and critical care medicine·2026
Same author

Depemokimab reduces asthma exacerbations similarly to other biologics.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2026
Same author

Multidrug-resistant <i>Haemophilus influenzae</i> cluster of severe asthma from sputum bacteriome-resistome.

ERJ open research·2026
Same author

Early and Sustained Efficacy of Depemokimab in Type 2 Asthma: A Pooled Analysis of the SWIFT-1/-2 Studies.

The journal of allergy and clinical immunology. In practice·2026
Same author

Depemokimab demonstrates efficacy in patients with type 2 asthma with comorbid CRSwNP: Phase III SWIFT-1/-2 analysis.

Frontiers in allergy·2026
Same journal

Information and consent forms for sublingual immunotherapy.

Clinical allergy and immunology·2008
Same journal

Instructions and consent forms for subcutaneous allergen immunotherapy.

Clinical allergy and immunology·2008
Same journal

Prevention and treatment of anaphylaxis.

Clinical allergy and immunology·2008
Same journal

Adverse effects associated with sublingual immunotherapy.

Clinical allergy and immunology·2008
Same journal

Adverse effects and fatalities associated with subcutaneous allergen immunotherapy.

Clinical allergy and immunology·2008
Same journal

Unproven and controversial forms of immunotherapy.

Clinical allergy and immunology·2008
See all related articles

Area of Science:

  • Allergy and Immunology
  • Pharmacology

Background:

  • Histamine is a primary mediator of allergic rhinoconjunctivitis symptoms.
  • Non-sedating H1-receptor antagonists have improved treatment options since the 1980s.

Purpose of the Study:

  • To review the role of H1-antihistamines in managing allergic rhinoconjunctivitis.
  • To discuss the evolution and current status of H1-antihistamine therapy.

Main Methods:

  • Review of clinical trials and pharmacological data on H1-antihistamines.
  • Analysis of oral and topical H1-antihistamine efficacy and bioavailability.

Main Results:

  • Oral H1-antihistamines provide 24-hour control of nasal and ocular symptoms.
  • Topical H1-antihistamines offer comparable or greater efficacy with lower systemic absorption.

Related Experiment Videos

  • Current H1-antihistamines primarily target histamine-mediated symptoms.

    • Conclusions:

    • H1-antihistamines are crucial for managing histamine-driven allergic rhinoconjunctivitis symptoms.
    • While effective, they do not fully address all aspects of the disease.
    • Further development of H1-antihistamines with broader antiallergic activity is anticipated.